Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of RGX-501 in Homozygous Familial Hypercholesterolemia
2019-004496-39Phase 2Completed
- Sponsor
- REGENXBIO Inc.
- Start
- Nov 2020
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAV-hLDLR in familial hypercholesterolemia (FH), sponsored by REGENXBIO Inc. Primary endpoints: Incidence of adverse events over time and Incidence of serious adverse events over time. Started Nov 2020; status: completed.
02
Drugs
AAV-hLDLR
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2019-004496-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004496-39.